RecruitingNCT06626360

Screening for Malnutrition in Obese Patients

SCreening fOr Malnutrition and Obesity in Patients With COVID-19 and Other Diseases


Sponsor

HAN University of Applied Sciences

Enrollment

2,000 participants

Start Date

Oct 2, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

More than half of the Dutch population is overweight or obese, which is associated with an increased risk of COVID-19 and worse outcomes during a COVID-19 infection. In addition, malnutrition and loss of muscle mass are often reported with COVID-19, as well as with cancer and other diseases. Malnutrition and overweight or obesity can coexist, even within the same individual. It is still unclear which mechanisms contribute to the worse outcomes of COVID-19 and other diseases in case of overweight, malnutrition, and a combination of both. The aim of this study is to identify which parameters are associated with worse disease outcomes through literature research and database research (COVID-19 and cancer, more than 150.000 participants). In addition, a clinical study will be conducted aiming to develop a simple screening tool for the recognition of the coexistence of malnutrition and overweight or obesity in clinical practice.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with malnutrition or risk of malnutrition and overweight and obese adults. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(3)

OLVG

Amsterdam, Netherlands

Ziekenhuis Gelderse Vallei

Ede, Netherlands

ErasmusMC

Rotterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06626360


Related Trials